8-K 1 a06-11717_18k.htm CURRENT REPORT OF MATERIAL EVENTS OR CORPORATE CHANGES

 

UNITED STATES

 

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

May 10, 2006

Date of Report (Date of earliest
event reported)

 

NeoRx Corporation

(Exact Name of Registrant as Specified in Charter)

 

Washington

 

0-16614

 

91-1261311

(State or Other Jurisdiction
of Incorporation)

 

(Commission File No.)

 

(IRS Employer
Identification No.)

 

 

 

 

 

300 Elliott Avenue West, Suite 500, Seattle, WA

 

98119-4114

(Address of principal executive offices)

 

(Zip Code)

 

(206) 281-7001

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 


 

Section 8 – Other Events

 

Item 8.01.                                          Other Events.

 

On May 10, 2006, NeoRx Corporation announced that it had treated the first patient in a Phase I/II clinical trial of picoplatin for the potential front-line treatment of colorectal cancer. The Company also announced that it will be changing its name to Poniard Pharmaceuticals, Inc. effective June 16, 2006 and plans to relocate its headquarters to San Francisco by the beginning of the third quarter of 2006. See press release dated May 10, 2006 attached hereto as Exhibit 99.1 and incorporated herein by reference.

 

Section 9 – Financial Statements and Exhibits

 

Item 9.01.                                          Financial Statements and Exhibits.

 

(d)                                  Exhibits.

 

99.1 - Press release dated May 10, 2006.

 

1


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

NeoRx Corporation

 

 

Dated: May 12, 2006

By:

/s/Susan D. Berland

 

 

 

Name: Susan D. Berland

 

 

Title: Chief Financial Officer

 

2


 

EXHIBIT INDEX

 

Exhibit No.

 

Description

99.1

 

Press Release dated May 10, 2006

 

3